Adenosine receptors in the nervous system: Pathophysiological implications

Progress in Neurobiology

Volumn 68, Issue 6, 2002, Pages 377-392

  Ribeiro, J A ^a   Sebastiao A M ^a   De Mendonca A ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; CAFFEINE; THEOPHYLLINE;

ALZHEIMER DISEASE; ANXIETY; AROUSAL; CELL MATURATION; COGNITION; DRUG DEPENDENCE; EPILEPSY; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; MEMORY; NERVE CELL DEGENERATION; NERVE CELL LESION; NEUROPATHIC PAIN; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN INTERACTION; RESPIRATION CONTROL; REVIEW; SCHIZOPHRENIA; SLEEP;

EID: 0036973951     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0082(02)00155-7     Document Type: Review

References (172)

1. Abbracchio M.P., Cattabeni F. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases. Ann. N. Y. Acad. Sci. 890:1999;79-92.
2. 3 receptors in rat brain. Mol. Pharmacol. 48:1995;1038-1045.
3. Aden U., Herlenius E., Tang L.Q., Fredholm B.B. Maternal caffeine intake has minor effects on adenosine receptor ontogeny in the rat brain. Pediatr. Res. 48:2000;177-183.
4. Akhondzadeh S., Shasavand E., Jamilian H., Shabestari O., Kamalipour A. Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. J. Clin. Pharm. Ther. 25:2000;131-137.
5. Andresen B.T., Gillespie D.G., Mi Z., Dubey R.K., Jackson E.K. Role of adenosine A(1) receptors in modulating extracellular adenosine levels. J. Pharmacol. Exp. Ther. 291:1999;76-80.
6. Antle M.C., Steen N.M., Mistlberger R.E. Adenosine and caffeine modulate circadian rhythms in the Syrian hamster. NeuroReport. 12:2001;2901-2905.
7. Ascherio A., Zhang S.M., Hernan M.A., Kawachi I., Colditz G.A., Speizer F.E., Willett W.C. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 50:2001;56-63.
8. 2A receptor gene. J. Neurosci. 22:2002;9210-9220.
9. Barraco R.A., Aggarwal A.K., Phillis J.W., Moron M.A., Wu P.H. Dissociation of the locomotor and hypotensive effects of adenosine analogues in the rat. Neurosci. Lett. 48:1984;139-144.
10. 1 adenosine receptors mimics the electroencephalographic effects of sleep deprivation. Brain Res. 692:1995;79-85.
11. 1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. J. Neurosci. 22:2002;9122-9133.
12. Boulenger J.-P., Uhde T.W., Wolff E.A., Post R.M. Increased sensitivity to caffeine in patients with panic disorders. Arch. Genet. Psychiatr. 41:1984;1067-1071.
13. Bouvier M. Oligomerization of G-protein-coupled transmitter receptors. Nat. Rev. Neurosci. 2:2001;274-286.
14. 6-(2,2-Diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity. J. Med. Chem. 30:1987;1709-1711.
15. Brundege J.M., Williams J.T. Increase in adenosine sensitivity in the nucleus accumbens following chronic morphine treatment. J. Neurophysiol. 87:2002;1369-1375.
16. Burnstock, G., 1978. A basis for distinguishing two types of purinergic receptor. In: Straub, R.W., Bollis, L. (Eds.), Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach. Raven Press, New York, pp. 107-118.
17. 1 receptor binding and function by 2-amino-3-benzoylthiophenes. J. Pharmacol. Exp. Ther. 38:1990;939-949.
18. Capasso A., Loizzo A. Purinoreceptors are involved in the control of acute morphine withdrawal. Life Sci. 69:2001;2179-2188.
19. 1 receptors in rat hippocampal slices. Neurochem. Res. 27:2002;1699-1703.
20. Cassada D.C., Tribble C.G., Kaza A.K., Fiser S.M., Long S.M., Linden J., Rieger J.M., Kron I.L., Kern J.A. Adenosine analogue reduces spinal cord reperfusion injury in a time-dependent fashion. Surgery. 130:2001;230-235.
21. 3 adenosine receptors improves tolerance to ischemia-reperfusion injury in mouse myocardium. Am. J. Physiol. Heart Circ. Physiol. 281:2001;H1751-H1758.
22. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 19:1999;9192-9200.
23. 2A adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21:2001;RC143.
24. Collier H.O., Cuthbert N.J., Francis D.L. Character and meaning of quasi-morphine withdrawal phenomena elicited by methylxanthines. Fed. Proc. 40:1981;1513-15188.
25. 2A receptor activation modulates nicotinic autoreceptor function at the rat neuromuscular junction. Eur. J. Pharmacol. 271:1994a;349-355.
26. 3H ]-acetylcholine release from the rat motor nerve endings Br. J. Pharmacol. 111:1994b;582-588.
27. Correia-de-Sá P., Sebastião A.M., Ribeiro J.A. Inhibitory and excitatory effects of adenosine receptor agonists on evoked transmitter release from phrenic nerve endings of the rat. Br. J. Pharmacol. 103:1991;1614-1620.
28. 2A facilitatory adenosine receptor activation balance depends on motor nerve stimulation paradigm at the rat hemidiaphragm. J. Neurophysiol. 76:1996;3910-3919.
29. 3H ]-acetylcholine release from the rat motor nerve terminals Neurosci. Lett. 309:2001;101-104.
30. 2B receptor. Nature. 407:2000;747-750.
31. Cunha R.A. Adenosine as a modulator and as a homeostatic regulator in the nervous system: distinct roles, different sources and different receptors. Neurochem. Int. 38:2001;107-125.
32. 3H ]GABA release from rat hippocampal nerve terminals Neuropharmacology. 39:2000;1156-1167.
33. 2A receptors in the rat hippocampus. Brain Res. 649:1994;208-216.
34. Cunha R.A., Correia-de-Sá P., Sebastião A.M., Ribeiro J.A. Preferential activation of excitatory adenosine receptors at rat hippocampal and neuromuscular synapses by adenosine formed from adenine nucleotides. Br. J. Pharmacol. 119:1996;253-260.
35. Dall'Igna O.P., Dietrich M.O., Hoffmann A., Neto W., Vendite D., Souza D.O., Lara D.R. Catalepsy and hypolocomotion induced by a nitric oxide donor: attenuation by theophylline. Eur. J. Pharmacol. 432:2001;29-33.
36. Daly J.W., Fredholm B.B. Caffeine: an atypical drug of dependence. Drug Alcohol Depend. 51:1998;199-206.
37. de Mendonça A., Ribeiro J.A. Endogenous adenosine modulates long-term potentiation in the hippocampus. Neuroscience. 62:1994;385-390.
38. 1 receptor activation in the rat hippocampus. Br. J. Pharmacol. 121:1997;1541-1548.
39. de Mendonça A., Ribeiro J.A. Adenosine and synaptic plasticity. Drug Dev. Res. 52:2001;283-290.
40. 1 receptor activation. NeuroReport. 6:1995;1097-1100.
41. de Mendonça A., Almeida T., Bashir Z.I. Endogenous adenosine attenuates long-term depression and depotentiation in the CA1 region of the rat hippocampus. Neuropharmacology. 36:1997;161-167.
42. de Mendonça A., Sebastião A.M., Ribeiro J.A. Adenosine: does it have a neuroprotective role after all? Brain Res. Rev. 33:2000;258-274.
43. Deckert J., Morgan P.F., Marangos P.J. Adenosine uptake site heterogeneity in the mammalian CNS? Uptake inhibitors as probes and potential neuropharmaceuticals. Life Sci. 42:1988;1331-1345.
44. Delicado E.G., Rodrigues A., Sen R.P., Sebastião A.M., Ribeiro J.A., Miras-Portugal M.T. Effect of N-ethylcarboxamidoadenosine (NECA) on adenosine transport in cultured chromaffin cells. J. Neurochem. 54:1990;1941-1946.
45. 2 receptors for dopamine in human striatum. NeuroReport. 12:2001;1831-1834.
46. Diaz-Hernandez M., Pereira M.F., Pintor J., Cunha R.A., Ribeiro J.A., Miras-Portugal M.T. Modulation of the rat hippocampal dinucleotide receptor by adenosine receptor activation. J. Pharmacol. Exp. Ther. 301:2002;441-450.
47. Di Iorio P., Kleywegt S., Ciccarelli R., Traversa U., Andrew C.M., Crocker C.E., Werstiuk E.S., Rathbone M.P. Mechanisms of apoptosis induced by purine nucleosides in astrocytes. Glia. 38:2002;179-190.
48. Dixon A.K., Gubitz A.K., Sirinathsinghji D.J., Richardson P.J., Freeman T.C. Tissue distribution of adenosine receptor mRNAs in the rat. Br. J. Pharmacol. 118:1996;1461-1468.
49. 2A receptor in the rat striatum. J. Neurochem. 69:1997;315-321.
50. 2 receptors as potential pharmacotherapy for schizophrenia. I. Adenosine agonists. Ann. Pharmacother. 33:1999;480-488.
51. Doody R.S., Stevens J.C., Beck C. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 56:2001;1154-1166.
52. Dragunow M. Adenosine: the brain's natural anticonvulsivant? Trends Pharmacol. Sci. 7:1986;128-130.
53. Drury A.N., Szent-Györgyi A. The physiological activity of adenine compounds with espetial reference to their action upon the mammalian heart. J. Physiol. 68:1929;213-237.
54. Dunwiddie T.V. Adenosine and suppression of seizures. Adv. Neurol. 79:1999;1001-1009.
55. Dunwiddie T.V., Masino S.A. The role and regulation of adenosine in the central nervous system. Ann. Rev. Neurosci. 24:2001;31-55.
56. Edwards F.A., Gibb A.J., Colquhoun D. ATP receptor-mediated fast synaptic currents in the central nervous system. Nature. 359:1992;144-147.
57. Eisenach J.C., Hood D.D., Curry R. Phase I safety assessment of intrathecal injection of an American formulation of adenosine in humans. Anaesthesiology. 96:2002;24-28.
58. 1 receptors regulate the response of the hamster circadian clock to light. Eur. J. Pharmacol. 414:2001;45-53.
59. Engler R.L. Adenosine, the signal of life? Circulation. 84:1991;951-954.
60. Eschalier, A., Ardid, D., Dubray, C., 1999. Tricyclic and other antidepressants as analgesics. In: Saynok, J., Cowan, A. (Eds.), Novel Aspects of Pain Management: Opioids and Beyond. Wiley, New York, pp. 301-319.
61. Esser M.J., Sawynok J. Caffeine blockade of the thermal antihyperalgesic effect of acute amitriptyline in a rat model of neuropathic pain. Eur. J. Pharmacol. 399:2000;131-139.
62. Esser M.J., Chase T., Allen G.V., Sawynok J. Chronic administration of amitriptyline and caffeine in a rat model of neuropatic pain. Eur. J. Pharmacol. 430:2001;211-218.
63. Ferrarese C., Aliprandi A., Tremolizzo L., Stanzani L., De Micheli A., Dolara A., Frattola L. Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology. 57:2001;671-675.
64. Ferré S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology. 133:1997;107-120.
65. 2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. U.S.A. 88:1991;7238-7241.
66. 2 receptors in rat neostriatal membranes. Eur. J. Pharmacol. 244:1993;311-315.
67. Ferré S., Fredholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20:1997;482-487.
68. 1 receptors modulate anxiety in CD1 mice. Psychopharmacology (Berl.). 136:1998;311-319.
69. Fredholm B.B., Bätig K., Holmén J., Nehlig A., Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51:1999;83-133.
70. Fredholm B.B., Ijzerman A.P., Jacobson K.A., Klotz K.-N., Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53:2001;527-552.
71. Fuxe K., Stromberg I., Popoli P., Rimondini-Giorgini R., Torvinen M., Ogren S.O., Franco R., Agnati L.F., Ferré S. Adenosine receptors and Parkinson's disease. Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum. Adv. Neurol. 86:2001;345-353.
72. 1-adenosine and D(2)-dopamine receptor genes in rat peripheral arterial chemoreceptors during postnatal development. Brain Res. 872:2000;1-10.
73. 1 receptors form functionally interacting heteromeric complexes. Proc. Natl. Acad. Sci. U.S.A. 97:2000;8606-8611.
74. Ginsborg B.L., Hirst G.D.S. The effect of adenosine on the release of the transmitter from the phrenic nerve of the rat. J. Physiol. Lond. 224:1972;629-645.
75. Glass M., Dragunow M., Faull R.L. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience. 97:2000;505-519.
76. 2+ uptake through class A calcium channels in rat hippocampal CA3 but not CA1 synaptosomes Neurosci. Lett. 238:1997;73-77.
77. Greengard P. The neurobiology of slow synaptic transmission. Science. 294:2001;1024-1030.
78. 2A receptor antagonist in MPTP-treated monkeys. Neurology. 52:1999;1673-1677.
79. 3H ]adenosine from rat brain synaptosomal preparations J. Neurochem. 64:1995;2105-2110.
80. 2A receptor involves activation of both N- and P-type calcium channels by different G proteins and protein kinases in the same striatal nerve terminals. J. Neurochem. 67:1996;374-381.
81. 3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. J. Mol. Cell. Cardiol. 33:2001;825-830.
82. Hardingham G.E., Fukunaga Y., Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5:2002;405-414.
83. 2 receptor blockade on spatial memory performance of rats: selective enhancement of reference memory retention during the light period. Behav. Brain Res. 118:2001;43-52.
84. 2A receptors in the caudate-putamen of rats. J. Neurosci. 14:2001;1287-1293.
85. Heath P.R., Shaw P.J. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve. 26:2002;438-458.
86. Hervé D., Le Moine C., Corvol J.C., Belluscio L., Ledent C., Fienberg A.A., Jaber M., Studler J.M., Girault J.A. Gα(olf) levels are regulated by receptor usage and control dopamine and adenosine action in the striatum. J. Neurosci. 21:2001;4390-4399.
87. Hoppenbrouwers, M.-L., Bussche, G.V., 1989. Mioflazine, a nucleoside transport inhibitor is it effective as a sleep promoter in humans? In: Wauquier, A., et al. (Eds.), Slow Wave Sleep: Pathophysiological and Functional Aspects. Raven Press, New York, pp. 301-309.
88. Huganir R.L., Delcour A.H., Greengard P., Hess G.P. Phosphorylation of the nicotinic acetylcholine receptor regulates its rate of desensitisation. Nature. 321:1986;774-776.
89. Ijzerman A., Kourounakis A., van der Klein P. Allosteric modulation of G protein-coupled receptors. Farmaco. 56:2001;67-70.
90. Impagnatiello F., Bastia E., Ongini E., Monopoli A. Adenosine receptors in neurological disorders. Emerg. Therap. Targets. 4:2000;635-664.
91. Jacobson K.A., von Lubitz D.K., Daly J.W., Fredholm B.B. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol. Sci. 17:1996;108-113.
92. Jain N., Kemp N., Adeyemo O., Buchanan P., Stone T.W. Anxiolytic activity of adenosine receptor activation in mice. Br. J. Pharmacol. 116:1995;2127-2133.
93. 1 receptor allosteric enhancer PD 81,723 on agonist binding to brain and adipocyte membranes. Brain Res. 840:1999;75-83.
94. Jarvis M.F., Yu H., McGaraughty S., Wismer C.T., Mikusa J., Zhu C., Chu K., Kohlhaas K., Cowart M., Lee C.H., Stewart A.O., Cox B.F., Polakowski J., Kowaluk E.A. Analgesic and anti-inflammatory effects of A-286501, a novel orally active adenosine kinase inhibitor. Pain. 96:2002;107-118.
95. 1 receptor. Proc. Natl. Acad. Sci. U.S.A. 98:2001;9407-9412.
96. Johnson-Kozlow M., Kritz-Silverstein D., Barrett-Connor E., Morton D. Coffee consumption and cognitive function among older adults. Am. J. Epidemiol. 156:2002;842-850.
97. 2A antagonist: a novel anti-Parkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys. Ann. Neurol. 43:1998;507-513.
98. Keil G.J. II, DeLander G.E. Spinally-mediated antinociception is induced in mice by an adenosine kinase-inhibitor, but not by an adenosine deaminase-inhibitor. Life Sci. 51:1992;PL171-PL176.
99. Kendall D.A., Hill S.J. Adenosine inhibition of histamine-stimulated inositol phospholipid hydrolysis in mouse cerebral cortex. J. Neurochem. 50:1988;497-502.
100. 6-cyclopentyladenosine-elicited attenuation of evoked glutamate release is not sufficient to give complete protection against pilocarpine-induced seizures in rats. Neuropharmacology. 40:2001;657-667.
101. 2A receptor is not mediated by increases in cyclic AMP. J. Neurochem. 64:1995;2801-2809.
102. Klinger M., Freissmuth M., Nanoff C. Adenosine receptors: G protein-mediated signaling and the role of accessory proteins. Cell. Signal. 14:2002;99-108.
103. Knapp C.M., Foye M.M., Cottam N., Ciraulo D.A., Kornetsky C. Adenosine agonists CGS 21680 and NECA inhibit the initiation of cocaine self-administration. Pharmacol. Biochem. Behav. 68:2001;797-803.
104. 2A receptor in the rat carotid body. Am. J. Physiol. Lung. Cell. Mol. Physiol. 279:2000;L273-L282.
105. 2A receptor agonist in sheep. Am. J. Physiol. 274:1998;R152-R159.
106. 2A receptors modulate sleep state and breathing in fetal sheep. J. Appl. Physiol. 91:2001;343-350.
107. olf in rat striatum. Mol. Pharmacol. 58:2000;771-777.
108. Kowaluk E.A., Jarvis M.F. Therapeutic potential of adenosine kinase inhibitors. Expert Opin. Invest. Drugs. 9:2000;551-564.
109. 1 adenosine receptor. Pain. 94:2001;315-324.
110. Lee F.S., Chao M.V. Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc. Natl. Acad. Sci. U.S.A. 98:2001;3555-3560.
111. 3 receptors. Am. J. Physiol. Renal Physiol. 278:2000;F380-F387.
112. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu. Rev. Pharmacol. Toxicol. 41:2001;775-787.
113. Lindskog M., Svenningsson P., Pozzi L., Kim Y., Fienberg A.A., Bibb J.A., Fredholm B.B., Nairn A.C., Greengard P., Fisone G. Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature. 418:2002;774-778.
114. Lipton S.A. Neuronal injury associated with HIV-1: approaches to treatment. Annu. Rev. Pharmacol. Toxicol. 38:1998;159-177.
115. 1 receptor inhibition. Neuroscience. 112:2002;319-329.
116. 6-substituted adenosine derivatives as partial agonists of rat brain adenosine receptors. Eur. J. Pharmacol. 334:1997;299-307.
117. Macallum G.E., Walker R.M., Barsoum N.J., Smith G.S. Preclinical toxicity studies of an adenosine agonist, N-(2,2-diphenylethyl)adenosine. Toxicology. 68:1991;21-35.
118. Maia L., de Mendonça A. Does caffeine intake protect from Alzheimer's disease? Eur. J. Neurol. 9:2002;1-6.
119. Mally J., Stone T.W. The effect of theophylline on Parkinsonian symptoms. J. Pharm. Pharmacol. 46:1994;515-517.
120. Manzoni O., Pujalte D., Williams J., Bockaert J. Decreased presynaptic sensitivity to adenosine after cocaine withdrawal. J. Neurosci. 18:1998;7996-8002.
121. 2A receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage. Ann. Neurol. 49:2001;727-735.
122. McGaraughty S., Cowart M., Jarvis M.F. Recent developments in the discovery of novel adenosine kinase inhibitors: mechanism of action and therapeutic potential. CNS Drug Rev. 7:2001;415-432.
123. McQueen D.S., Ribeiro J.A. Pharmacological characterization of the receptor involved in chemoexcitation induced by adenosine. Br. J. Pharmacol. 88:1986;615-620.
124. Monteiro E.C., Ribeiro J.A. Ventilatory effects of adenosine mediated by carotid body chemoreceptors in the rat. Naunyn Schmiedebergs Arch. Pharmacol. 335:1987;143-148.
125. 2A receptors as a basis for the treatment of Parkinson's disease. Neurol. Sci. 22:2001;71-72.
126. 2X receptors in CA3 pyramidal cells of rat hippocampal slices. J. Physiol. 535:2002;115-123.
127. Newby A.C. Adenosine as a retaliatory metabolite. Trends Biol. Sci. 9:1981;42-44.
128. Nieber K., Poelchen W., Illes P. Role of ATP in fast excitatory synaptic potentials in locus coeruleus neurones of the rat. Br. J. Pharmacol. 122:1997;423-430.
129. Ohta A., Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 414:2001;916-920.
130. Pak M.A., Haas H.L., Decking U.K., Schrader J. Inhibition of adenosine kinase increases endogenous adenosine and depresses neuronal activity in hippocampal slices. Neuropharmacology. 33:1994;1049-1053.
131. Pan H.L., Xu Z., Leung E., Eisenach J.C. Allosteric adenosine modulation to reduce allodynia. Anesthesiology. 95:2001;416-420.
132. 2X receptors in the CA1 neurons of the rat hippocampus. Eur. J. Neurosci. 10:1998;3898-3902.
133. 1-adenosine receptor activation in male rat pelvic ganglion neurons. J. Pharmacol. Exp. Ther. 299:2001;501-508.
134. Parkinson F.E., Sinclair C.J., Othman T., Haughey N.J., Geiger J.D. Differences between rat primary cortical neurons and astrocytes in purine release evoked by ischemic conditions. Neuropharmacology. 43:2002;836-846.
135. Phillis J.W. Potentiation of the action of adenosine on cerebral cortical neurones by tricyclic antidepressants. Br. J. Pharmacol. 83:1984;567-575.
136. Phillis J.W., Wu P.H. The effects of various centrally active drugs on adenosine uptake by the central nervous system. Comp. Biochem. Physiol. C: Comp. Pharmacol. 72:1982;179-187.
137. Poon A., Sawynok J. Antinociceptive and anti-inflammatory properties of an adenosine kinase inhibitor and an adenosine deaminase inhibitor. Eur. J. Pharmacol. 384:1999;123-138.
138. 2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J. Neurosci. 22:2002;1967-1975.
139. Porkka-Heinskanen T. Adenosine in sleep and wakefulness. Ann. Med. 31:1999;125-129.
140. Porkka-Heiskanen T., Strecker R.E., Thakkar M., Bjorkum A.A., Greene R.W., McCarley R.W. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science. 276:1997;1265-1268.
141. Rane K., Segerdahl M., Goiny M., Sollevi A. Intrathecal adenosine administration: a phase 1 clinical safety study in healthy volunteers, with additional evaluation of its influence on sensory thresholds and experimental pain. Anesthesiology. 89:1998;1108-1115.
142. 2 receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease. Brain Res. 831:1999;315-318.
143. 2A receptor interactions with receptors for other neurotransmitters and neuromodulators. Eur. J. Pharmacol. 375:1999;101-113.
144. Ribeiro, J.A., Sebastião, A.M., 1987. Adenosine, cyclic AMP and nerve conduction. In: Gerlach, E., Becker, B.F. (Eds.), Topics and Perspectives in Adenosine Research. Springer, Berlin, pp. 559-573.
145. Ribeiro J.A., Cunha-Reis D., Lopes L.V., Coelho J., Costenla A.R., Correia-de-Sá P., Cunha R.A., de Mendonça A., Sebastião A.M. Adenosine receptor interactions in the hippocampus. Drug Dev. Res. 52:2001;337-345.
146. Rivkees S.A., Zhao Z., Porter G., Turner C. Influences of adenosine on the fetus and newborn. Mol. Genet. Metab. 74:2001;160-171.
147. Ross G.W., Abbott R.D., Petrovitch H., Morens D.M., Grandinetti A., Tung K.H., Tanner C.M., Masaki K.H., Blanchette P.L., Curb J.D., Popper J.S., White L.R. Association of coffee and caffeine intake with the risk of Parkinson's disease. JAMA. 283:2000;2674-2679.
148. Sandner-Kiesling A., Li X., Eisenach J.C. Morphine-induced spinal release of adenosine is reduced in neuropathic rats. Anesthesiology. 95:2001;1455-1459.
149. Sattler R., Xiong Z., Lu W.Y., MacDonald J.F., Tymianski M. Distinct roles of synaptic and extrasynaptic NMDA receptors in excitotoxicity. J. Neurosci. 20:2000;22-33.
150. Sawynok J. Adenosine receptor activation and nociception. Eur. J. Pharmacol. 347:1998;1-11.
151. Schulte G., Fredholm B.B. Diverse inhibitors of intracellular signalling act as adenosine receptor antagonists. Cell Signal. 14:2002;109-113.
152. 2A antagonists in PD. Neurology. 58:2002;1154-1160.
153. Sebastião A.M., Ribeiro J.A. Interactions between adenosine and phorbol esters or lithium at the frog neuromuscular junction. Br. J. Pharmacol. 100:1990;55-62.
154. 2 receptor-mediated excitatory actions on the nervous system. Prog. Neurobiol. 48:1996;167-189.
155. Sebastião A.M., Ribeiro J.A. Fine-tuning neuromodulation by adenosine. Trends Pharmacol. Sci. 21:2000;341-346.
156. 1 receptors prevents, a facilitatory action of calcitonin gene-related peptide in the rat hippocampus. Br. J. Pharmacol. 129:2000;374-380.
157. Sebastião A.M., de Mendonça A., Ribeiro J.A. Neuroprotection during hypoxic insults: role of adenosine. Drug Dev. Res. 52:2001a;291-295.
158. Sebastião A.M., de Mendonça A., Moreira T., Ribeiro J.A. Activation of synaptic NMDA receptors by action potential-dependent release of transmitter during hypoxia impairs recovery of synaptic transmission on reoxygenation. J. Neurosci. 21:2001b;8564-8571.
159. Spyer K.M., Thomas T. A role for adenosine in modulating cardio-respiratory responses: a mini-review. Brain Res. Bull. 53:2000;121-124.
160. 2 adenosine receptors inhibit calcium influx through L-type calcium channels in rod photoreceptors of the salamander retina. J. Neurophysiol. 87:2002;351-360.
161. Stone, T.W., Collis, M.G., Williams, M., Miller, L.P., Karasawa, A., Hillaire-Buys, D., 1995. Adenosine: some therapeutic applications and prospects. In: Cuello, A.C., Collier, B. (Eds.), Pharmacological Sciences:
162. Straiker A.J., Borden C.R., Sullivan J.M. G-protein α subunits couple to differentially to receptors that mediate presynaptic inhibition of rat hippocampal synapses. J. Neurosci. 22:2002;2460-2468.
163. Sun M.K., Xu H., Alkon D.L. Pharmacological protection of synaptic function, spatial learning, and memory from transient hypoxia in rats. J. Pharmacol. Exp. Ther. 300:2002;408-416.
164. Ulugol A., Karadag H.C., Tamer M., Firat Z., Aslantas A., Dokmeci I. Involvement of adenosine in the anti-allodynic effect of amitriptyline in streptozotocin-induced diabetic rats. Neurosci. Lett. 328:2002;129-132.
165. van Dongen H.P., Price N.J., Mullington J.M., Szuba M.P., Kapoor S.C., Dinges D.F. Caffeine eliminates psychomotor vigilance deficits from sleep inertia. Sleep. 24:2001;813-819.
166. von Arnim C.A., Timmler M., Ludolph A.C., Riepe M.W. Adenosine receptor up-regulation: initiated upon preconditioning but not upheld. NeuroReport. 11:2000;1223-61226.
167. von Lubitz D.K. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? Eur. J. Pharmacol. 371:1999;85-102.
168. 3 receptors in cerebral ischemia. Neuronal death, recovery, or both? Ann. N. Y. Acad. Sci. 890:1999;93-106.
169. 1-like adenosine receptor. Proc. Natl. Acad. Sci. U.S.A. 98:2001;7617-7622.
170. 2A adenosine receptor antagonist, counteracts Parkinsonian-like muscle rigidity in rats. Synapse. 41:2001;160-171.
171. 1 adenosine receptors. J. Neurosci. 22:2002;1248-1255.
172. Zimmermann H., Braun N. Ecto-nucleotidases - molecular structures, catalytic properties, and functional roles in the nervous system. Prog. Brain Res. 120:1999;371-385.